Abstract

Background: Rheumatic heart disease (RHD) is deposition of immune complexes which cause malfunction of the heart valves. Percutaneous mitral balloon valvuloplasty (PMBV) is established treatment options in patients with symptomatic moderate or severe rheumatic mitral valve disease. However, PMBV is not the preferred option in patients with mitral stenosis and moderate mitral regurgitation (MR) given to the risk of severe MR. The aim of this study was to evaluate the safety and feasibility of PMBV in symptomatic MS patients with moderate MR by comparing the post-procedural parameters with those of MS patients with mild or no MR.
Methods: Among 104 patients with symptomatic mitral stenosis, 10 patients with moderate MR were classified as group two while 94 patients who had mild or none MR were classified as group one in the present work. All patients underwent PMBV and pre- and post-procedural mitral valve area, mitral regurgitations were recorded and cardiovascular events and complications were assessed in 30 days.
Results: The only difference in both groups before and after the procedure was the severity of the MR. Cardiovascular death was none for both groups in 30 days. In group one, there were 3 patients and in group two there were 1 patient who occurred severe MR after PMBV. All patients who had post-procedural severe MR required mitral valve replacement in 30 days due to severe MR in group 1. The composite complication rate was similar between the groups.
Conclusions: PMBV might be an alternative treatment option for selected patient who had significant MS with moderate MR.

Key words: Mitral Valve Valvuloplasty; Mitral Valve Stenosis; Mitral Valve Regurgitation